<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN">
<html>

<!-- Mirrored from www.naturesbounty.com/vf/healthnotes/HN_Live/Spanish/Es-Supp/NADH.ref.htm by HTTrack Website Copier/3.x [XR&CO'2005], Thu, 03 Mar 2005 14:34:07 GMT -->
<head>
<meta http-equiv="Content-Type" content="text/html; charset=ISO-8859-1">
<meta name="Language" content="es">
<meta name="ContentID" content="2890007">
<meta name="Category" content="Supp">
<meta name="Article" content="NADH">
<title>Nicotinamida Aden&#237;n Dinucle&#243;tido-Referencias</title>
<link type="text/css" rel="stylesheet" href="../Styles/hnqrHtml.css">
<base target="_self">
</head>
<body>
<div id="Article-Title" class="Article-Title"><a name="Article-Title"></a> 

<p class="Article-Title">NADH</p>
</div>

<div id="Reference-List" class="Reference-List">
<p class="Reference-Autofill"><a href="NADH.htm">Volver al art&#237;culo.</a></p>

<h3>Referencias para el art&#237;culo</h3>

<ol class="Reference-List">
<li class="Ref">Kuhn W, Muller T, Winkel R, et al. Parenteral application of NADH in
Parkinson&#8217;s disease: clinical improvement partially due to stimulation of endogenous
levodopa biosynthesis. <em>J Neural Transm</em> 1996;103:1187&#8211;93.</li>

<li class="Ref">Birkmayer W, Birkmayer JGD, Vrecko K, et al. The clinical benefit of NADH as
stimulator of endogenous L-Dopa biosynthesis in Parkinsonian patients. In: Streifler MB,
Korczyn AD, Melamed E, et al. (eds). <em>Advances in Neurology,</em> vol. 53 (Parkinsons
Disease: Anatomy, Pathology, and Therapy). New York: Raven Press, 1990, 545&#8211;9.</li>

<li class="Ref">Birkmayer JG, Vrecko C, Volc D, Birkmayer W. Nicotinamide adenine dinucleotide
(NADH)&#8212; a new therapeutic approach to Parkinson&#8217;s disease. Comparison of oral and
parenteral application. <em>Acta Neurol Scand Supp</em> 1993;146:32&#8211;5.</li>

<li class="Ref">Dizdar N, Kagedal B, Lindvall B. Treatment of Parkinson&#8217;s disease with
NADH. <em>Acta Neurol Scand</em> 1994;90:345&#8211;7.</li>

<li class="Ref">Birkmayer JG. Coenzyme nicotinamide adenine dinucleotide: new therapeutic
approach for improving dementia of the Alzheimer type. <em>Ann Clin Lab Sci</em>
1996;26:1&#8211;9.</li>

<li class="Ref">Birkmayer JGD, Birkmayer W. The coenzyme nicotinamide adenine dinucleotide
(NADH) as biological antidepressive agent: experience with 205 patients. <em>New Trends Clin
Neuropharmacol</em> 1991;5:19&#8211;25.</li>

<li class="Ref">Forsyth LM, MacDowell-Carnciro AL, Birkmayer GD, et al. The use of NADH as a
new therapeutic approach in chronic fatigue syndrome. Presented at the annual meeting of the
American College of Allergy, Asthma &amp; Immunology, 1998.</li>
</ol>
</div>
</body>

<!-- Mirrored from www.naturesbounty.com/vf/healthnotes/HN_Live/Spanish/Es-Supp/NADH.ref.htm by HTTrack Website Copier/3.x [XR&CO'2005], Thu, 03 Mar 2005 14:34:07 GMT -->
</html>

